Determination of Nitrosamine Impurities Using the Ultivo Triple Quadrupole LC/MS

Importance of the Topic

Trace-level nitrosamine impurities in angiotensin II receptor blocker (ARB) pharmaceuticals have emerged as a critical quality and safety concern due to their potential carcinogenicity. Regulatory agencies such as the FDA and EMA have mandated sensitive analytical methods to detect and quantify these genotoxic compounds at sub-ng/mL levels, ensuring patient safety and product compliance.

Objectives and Study Overview

This study demonstrates a robust LC–MS/MS method using the Agilent Ultivo triple quadrupole system to simultaneously detect and quantify 12 nitrosamine impurities in ARB drug formulations. The primary goals were to achieve low limits of quantitation, wide linear dynamic ranges, high reproducibility, and compliance with regulatory LOQ requirements.

Methodology and Instrumentation

Sample Preparation and Standards

• Twelve nitrosamine standards (NDMA, NDEA, NMBA, NEIPA, NDIPA, NDBA, NMEA, NPyR, NPIP, NMPhA, NMIPA, N-tert-butyl-N-ethyl nitrosamine) obtained from PS3 Labs.
• Standards diluted in water/methanol with 0.2% formic acid.

Liquid Chromatography Configuration

• Agilent 1290 Infinity II pump, multisampler and column thermostat.
• Poroshell HPH C18 column (2.1×100 mm, 1.9 µm), 40 °C.
• Mobile phase A: 0.2% formic acid in water; B: methanol; flow 0.4 mL/min; 10 min gradient.

Mass Spectrometry Configuration

• Agilent Ultivo QqQ with APCI source in positive ion mode.
• Dynamic MRM transitions optimized for each analyte via MassHunter Optimizer.
• Source conditions: 300 °C drying gas, 6 L/min; 350 °C APCI heater; 55 psi nebulizer; 3,000 V capillary.

Main Results and Discussion

The method achieved limits of detection between 0.025 and 0.075 ng/mL and quantitation limits of 0.05 to 0.1 ng/mL for most analytes. Calibration was linear from low-ppb to 100 ng/mL with correlation coefficients above 0.996. Signal-to-noise ratios at LOQ exceeded 12 for all compounds. Accuracy at the LOQ level ranged between 84% and 112%, and intra-assay precision (CV) remained below 15%. Overlayed dMRM chromatograms confirmed clear separation and consistent retention times for all 12 nitrosamines.

Benefits and Practical Applications

This sensitive and high-throughput method allows pharmaceutical QC laboratories to monitor nitrosamine impurities in ARB products effectively. Its wide dynamic range facilitates both trace-level screening and routine batch testing with minimal method adjustments.

Future Trends and Applications

Advances in LC–MS technology and automated data processing are expected to further reduce analysis time and improve detection limits. Integration with high-resolution mass spectrometry and predictive risk assessment may expand this workflow to other drug classes susceptible to nitrosamine contamination.

Conclusion

The Agilent Ultivo LC/TQ method provides a rapid, accurate, and reproducible approach for quantifying a broad panel of nitrosamine impurities at regulatory-relevant levels. Its implementation supports pharmaceutical manufacturers in ensuring product safety and compliance.

References

1. FDA Updates and Press Announcements on ARB Recalls (valsartan, losartan).
2. FDA Guidance: RapidFire-MS/MS Screening of Nitrosamine Impurities.
3. FDA Guidance: LC-HRMS Method for Nitrosamine Determination in ARB Drugs.